Program
1200mg of tqb2928 injection
A development code. Also written as “1200mg of TQB2928 injection+Anlotinib”, “1800mg of TQB2928 injection+Anlotinib” and “TQB2928 injection + Almonertinib Mesilate Tablets”.
In Sino Biopharmaceutical’s pipeline, CD47单抗
. Its studies are mostly in Osteosarcoma · Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 21 open or running | phase 1since May 27, 2024 | May 27, 2024 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB2928
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 27, 2024First study: phase 1 study in OsteosarcomaFirst studyNCT06438783 · 20 enrolled · China
- Sep 1, 2024Phase 1 study in Advanced Non-small Cell Lung CancerNCT06585059 · 20 planned · China
TargetBeta
“CD47单抗”the company's pipeline, read by Claude · source
Other programs on CD47
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ligufalimabrule | Akeso | phase 3 | 11 |
| evorpaceptrule | alx-oncology-inc | phase 3 | 9 |
| Anti-PD-1/CD47 Fusion Protein HX009rule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 5 |
| CD47 Antagonist AUR103 Calciumrule | Dr. Reddy's Laboratories | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06585059Advanced Non-small Cell Lung Cancer · China | 1 | Not yet recruiting | Dec 2025 | 20 |
| NCT06438783Osteosarcoma · China | 1 | Terminated | Jun 18, 2025 | 20 |
How it is read
Names in the registry
- “1200mg of TQB2928 injection+Anlotinib”, 1 entry
- “1800mg of TQB2928 injection+Anlotinib”, 1 entry
- “TQB2928 injection + Almonertinib Mesilate Tablets”, 1 entry
Codes read as this program: TQB2928.
Conditions, from the studies’ own filings
- Osteosarcoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.